Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB.
BACKGROUND
Captopril is an angiotensin-converting enzyme (ACE) inhibitor widely used in the treatment of arterial hypertension and cardiovascular diseases. Our objective was to study whether captopril is able to attenuate the cardiac inflammatory process associated with arterial hypertension.


METHODS
Left ventricle mRNA expression and plasma levels of pro-inflammatory (interleukin-1beta (IL-1beta) and IL-6) and anti-inflammatory (IL-10) cytokines, were measured in spontaneously hypertensive rats (SHR) and their control normotensive, Wistar-Kyoto (WKY) rats, with or without a 12-week treatment with captopril (80 mg/Kg/day; n = six animals per group). To understand the mechanisms involved in the effect of captopril, mRNA expression of ACE, angiotensin II type I receptor (AT1R) and p22phox (a subunit of NADPH oxidase), as well as NF-kappaB activation and expression, were measured in the left ventricle of these animals.


RESULTS
In SHR, the observed increases in blood pressures, heart rate, left ventricle relative weight, plasma levels and cardiac mRNA expression of IL-1beta and IL-6, as well as the reductions in the plasma levels and in the cardiac mRNA expression of IL-10, were reversed after the treatment with captopril. Moreover, the mRNA expressions of ACE, AT1R and p22phox, which were enhanced in the left ventricle of SHR, were reduced to normal values after captopril treatment. Finally, SHR presented an elevated cardiac mRNA expression and activation of the transcription nuclear factor, NF-kappaB, accompanied by a reduced expression of its inhibitor, IkappaB; captopril administration corrected the observed changes in all these parameters.


CONCLUSIONS
These findings show that captopril decreases the inflammation process in the left ventricle of hypertensive rats and suggest that NF-kappaB-driven inflammatory reactivity might be responsible for this effect through an inactivation of NF-kappaB-dependent pro-inflammatory factors.
Miguel-Carrasco
José L
JL
Departamento de Fisiología y Zoología, Facultad de Farmacia, Universidad de Sevilla, E-41012 Sevilla, Spain. vazquez@us.es.
Zambrano
Sonia
S
Blanca
Antonio J
AJ
Mate
Alfonso
A
Vázquez
Carmen M
CM
Immunopharmacol Immunotoxicol. 1995 Aug;17(3):471-91
8576541
Hypertension. 2007 Mar;49(3):695-703
17283252
Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1226-32
18178715
Eur J Pharmacol. 2010 Feb 10;627(1-3):242-50
19903466
Circulation. 1997 Dec 2;96(11):4002-10
9403625
Cell Immunol. 2010;260(2):92-7
19854435
Am J Physiol Regul Integr Comp Physiol. 2000 Mar;278(3):R572-7
10712274
Eur J Pharmacol. 2010 Apr 25;632(1-3):65-72
20123095
J Am Coll Cardiol. 2004 Jul 21;44(2):362-8
15261932
Curr Hypertens Rep. 2002 Apr;4(2):167-71
11884273
Circ Res. 2007 Sep 28;101(7):734-41
17673672
J Hypertens Suppl. 2009 Aug;27(6):S5-10
19633453
Hypertension. 2000 Jul;36(1):103-9
10904020
Kidney Int. 2008 Feb;73(3):288-99
18033243
Sheng Li Xue Bao. 2006 Aug 25;58(4):318-23
16906331
J Biol Chem. 2004 May 7;279(19):20363-8
15001568
Am J Physiol Regul Integr Comp Physiol. 2006 Dec;291(6):R1817-24
16840655
Hypertension. 2000 Jan;35(1 Pt 2):193-201
10642297
Hypertension. 1996 Jan;27(1):14-8
8591877
Hypertens Res. 2007 May;30(5):451-7
17587757
Circulation. 2002 May 14;105(19):2296-302
12010913
Hypertension. 2003 Feb;41(2):266-73
12574093
Hypertension. 2009 Sep;54(3):619-24
19620507
J Mol Cell Cardiol. 2006 Oct;41(4):580-91
16949095
Hypertension. 2005 Oct;46(4):943-7
16087785
Am J Physiol Heart Circ Physiol. 2005 Jan;288(1):H111-5
15308481
Exp Physiol. 1999 Nov;84(6):1095-105
10564706
Kidney Int. 2006 Jul;70(1):170-6
16710350
Circulation. 2005 Oct 18;112(16):2436-45
16216963
Physiol Res. 2000;49(1):1-10
10805399
Exp Eye Res. 2006 Sep;83(3):651-7
16698015
Curr Opin Nephrol Hypertens. 2006 Mar;15(2):152-8
16481882
Hypertension. 1997 Dec;30(6):1621-7
9403592
J Lab Clin Med. 1993 Oct;122(4):395-403
8228553
Kidney Int. 1997 Oct;52(4):926-33
9328931
Biochem Biophys Res Commun. 2002 Aug 9;296(1):194-200
12147250
Biochem Biophys Res Commun. 1999 Apr 21;257(3):826-8
10208867
Am J Pathol. 1998 Dec;153(6):1825-37
9846973
Am J Physiol Regul Integr Comp Physiol. 2006 Sep;291(3):R760-7
16690767
Circulation. 2000 Oct 31;102(18):2243-8
11056100
Mol Cell Biochem. 2000 Sep;212(1-2):155-69
11108147
Hypertension. 1999 Jan;33(1 Pt 2):212-8
9931107
J Hypertens. 1993 Jun;11(6):611-22
8397240
J Cell Physiol. 2003 Jun;195(3):402-10
12704649
J Hypertens. 2005 Feb;23(2):435-44
15662233
Regul Pept. 2005 Aug 15;130(1-2):67-74
15908024
J Hypertens Suppl. 2009 Aug;27(6):S42-6
19633451
Clin Sci (Lond). 2007 Jun;112(7):375-84
17324119
J Hypertens. 2009 Mar;27(3):626-32
19262230
Redox Rep. 2004;9(6):354-9
15720832
Am J Hypertens. 2008 Nov;21(11):1231-7
18787523
Circ Res. 1999 Oct 15;85(8):e17-24
10521249
Toxicol Appl Pharmacol. 2000 Oct 15;168(2):123-30
11032767
Asian J Surg. 2002 Jul;25(3):203-8
12376215
Nat Protoc. 2006;1(2):581-5
17406285
Cardiovasc Pathol. 2004 Mar-Apr;13(2):71-8
15033155
Diabetes. 2002 Jun;51(6):1931-7
12031983
Eur J Clin Invest. 2001 Jan;31(1):31-6
11168436
J Mol Cell Cardiol. 1997 Dec;29(12):3365-74
9441842
Circulation. 1999 Sep 14;100(11):1223-9
10484544
J Mol Cell Cardiol. 2000 Feb;32(2):177-85
10722795